[Not a valid template]
AstraZeneca has restructured its management team, with a newly appointed executive to head North American operations from the company’s site near Wilmington.
Paul Hudson was named Executive Vice President, North America. He formerly served as Representative Director and President of AstraZeneca K. K., the Japanese subsidiary of AstraZeneca PLC. Hudson will be based in north Wilmington in the new position, according to AstraZeneca spokesman Tony Jewell.
Tony Zook – who at one point headed North American operations while also serving as president of AZ’s Maryland-based Medimmune – is leaving the company this month. Zook, most recently, served as Executive Vice President, Global Commercial.
Also leaving is President of Research and Development Martin Mackay,
The changes come after Pascal Soriot was named CEO, following the resignation of David Brennan, who had earlier headed American operations before going to the company’s London headquarters as CEO.
AstraZeneca has been struggling with the expirations of patents for blockbuster drugs. It has cut its workforce in Delaware and elsewhere while maintaining manufacturing and administrative operations in the state.
Commenting on Mackay and Zook, Soriot said: “I would like to thank Martin and Tony for their contribution and the exemplary leadership they have shown in their time at AstraZeneca. We wish them well in their future endeavors.”
Other management assignments are s follows:
- Simon Lowth, Chief Financial Officer and Executive Director
- Mene Pangalos, Executive Vice President, Innovative Medicines
- Bahija Jallal, Executive Vice President, MedImmune
- Briggs Morrison, Executive Vice President, Global Medicines Development
- Ruud Dobber, Executive Vice President, Europe
- Mark Mallon, Executive Vice President, International
- David Smith, Executive Vice President, Operations & IS
- Lynn Tetrault , Executive Vice President, Human Resources & Corporate Affairs
- Katarina Ageborg, Chief Compliance Officer
- Jeff Pott, General Counsel
The appointment of Executive Vice President, Global Portfolio & Product Strategy will be made at a later date.
